{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:37:16Z","timestamp":1792496236268,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.obpill.2026.100280","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:10:17Z","timestamp":1780038617000},"page":"100280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design of INFORMUS, a pragmatic, randomized, double-blind, placebo-controlled study of cardiovascular outcomes with the extended-release, fixed-dose combination of naltrexone and bupropion"],"prefix":"10.1016","volume":"19","author":[{"given":"Michael","family":"Kyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-2144","authenticated-orcid":false,"given":"David M.","family":"Savastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrilyn A.","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaize","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2026.100280_bib1","author":"Organization"},{"issue":"508","key":"10.1016\/j.obpill.2026.100280_bib2","article-title":"Obesity and severe obesity prevalence in adults: united States, August 2021-August 2023","author":"Emmerich","year":"2024","journal-title":"NCHS Data Brief"},{"issue":"7 Suppl","key":"10.1016\/j.obpill.2026.100280_bib3","first-page":"s176","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.obpill.2026.100280_bib4","article-title":"Obesity algorithm","author":"Tondt","year":"2024","journal-title":"Obes Med Assoc"},{"issue":"3","key":"10.1016\/j.obpill.2026.100280_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.obpill.2026.100280_bib6","article-title":"Cardiovascular safety of fixed-dose extended-release naltrexone\/bupropion in clinical practice","volume":"13","author":"Kyle","year":"2025","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2026.100280_bib7","series-title":"Phentermine HCl [Prescribing information]","year":"2024"},{"key":"10.1016\/j.obpill.2026.100280_bib8","series-title":"Contrave (naltrexone HCl and bupropion HCl) [Prescribing information]. Brentwood, TN: Currax Pharmaceuticals","year":"2025"},{"issue":"5","key":"10.1016\/j.obpill.2026.100280_bib9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity"},{"issue":"9741","key":"10.1016\/j.obpill.2026.100280_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.obpill.2026.100280_bib11","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.obpill.2026.100280_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.obpill.2026.100280_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14740338.2017.1247807","article-title":"Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone\/bupropion extended release and phentermine-topiramate extended release","volume":"16","author":"Halpern","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.obpill.2026.100280_bib14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.obpill.2026.100280_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/10543406.2013.860769","article-title":"A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring","volume":"24","author":"Zhao","year":"2014","journal-title":"J Biopharm Stat"},{"issue":"1","key":"10.1016\/j.obpill.2026.100280_bib16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11096-021-01330-2","article-title":"Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA adverse event reporting system (FAERS) databases 2013-2020","volume":"44","author":"Alsuhibani","year":"2022","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"10.1016\/j.obpill.2026.100280_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12020-024-04029-2","article-title":"Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: a single-centre experience","volume":"87","author":"Lui","year":"2025","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.obpill.2026.100280_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12724","article-title":"The real-world relationship between naltrexone\/bupropion treatment and weight loss in Canada: a retrospective chart review","volume":"15","author":"Wharton","year":"2025","journal-title":"Clin Obes"},{"issue":"12","key":"10.1016\/j.obpill.2026.100280_bib19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1808721","article-title":"Cardiovascular safety of lorcaserin in overweight or Obese patients","volume":"379","author":"Bohula","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.obpill.2026.100280_bib20","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41366-020-0544-4","article-title":"The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA adverse event report system database","volume":"44","author":"Gorelik","year":"2020","journal-title":"Int J Obes (Lond)"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:29:40Z","timestamp":1787988580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"alternative-id":["S2667368126000367"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100280","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of INFORMUS, a pragmatic, randomized, double-blind, placebo-controlled study of cardiovascular outcomes with the extended-release, fixed-dose combination of naltrexone and bupropion","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100280"}}